Cart
sales@molnova.com
Nurulimab
CAS No. 2168561-20-2
Nurulimab( —— )
Catalog No. M36820 CAS No. 2168561-20-2
Nurulimab (BCD-145) is an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) human monoclonal antibody with anti-cancer activity for the study of skin and musculoskeletal diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 299 | Get Quote |
|
| 5MG | 490 | Get Quote |
|
| 10MG | 787 | Get Quote |
|
| 25MG | 1132 | Get Quote |
|
| 50MG | 1518 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNurulimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNurulimab (BCD-145) is an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) human monoclonal antibody with anti-cancer activity for the study of skin and musculoskeletal diseases.
-
DescriptionNurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) humanized monoclonal antibody. Nurulimab can be can be used in research of melanoma.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2168561-20-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 34, No. 1, 2020.
molnova catalog
related products
-
MART-1 (26-35) (huma...
MART-1 (26-35) (human) TFA is an amino acid residue of 26-35 protein.
-
16-Epipyromesaconine
16-Epipyromesaconitine is a natural product that can be obtained by the pyrolysis of Mesaconitine.
-
Oxindole
Oxindole is an aromatic heterocyclic building block.?2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development.
